🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with CSPC Zhongnuo Pharmaceutical (Shijiazhuang) as lead sponsor. Synced 26 Sep 2026
10Current trials
9Recruiting now
3Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) is the lead sponsor of 10 current clinical trials in our China register. 9 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are SYH2053, SYH2070 and Abraxane. The most-studied condition is Non-familial Hypercholesterolemia and Mixed Hyperlipidemia.

ClinicalTrials.gov trials by status

  • Recruiting990%
  • Not yet open110%

Trials by phase

  • Phase 1440%
  • Phase 3330%
  • Phase 2220%
  • Not applicable110%
01

Clinical trials sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang)

10 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Study of SYH2062 Injection in Healthy Chinese Volunteers
NCT06842537 · ClinicalTrials.gov ↗ · Healthy Chinese Volunteers
Phase 1 Recruiting 2025-03 China
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2061
NCT07241910 · ClinicalTrials.gov ↗ · Healthy Subjects
Phase 1 Recruiting 2025-12 China
A Bioequivalence Study of PP3M in Patients With Schizophrenia
NCT07493551 · ClinicalTrials.gov ↗ · Schizophrenia
Not applicable Recruiting 2024-10 China
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2070 Injection
NCT07241923 · ClinicalTrials.gov ↗ · Healthy Subjects (HS)
Drug: SYH2070
Phase 1 Recruiting 2025-11 China
Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial Hypercholesterolemia
NCT07591298 · ClinicalTrials.gov ↗ · Diagnosed With HoFH
Phase 2 Recruiting 2026-05 China
Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Patients
NCT07096869 · ClinicalTrials.gov ↗ · Bioequivalence
Drug: Abraxane
Phase 1 Recruiting 2025-06 China
A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemia
NCT07695597 · ClinicalTrials.gov ↗ · Mixed Hyperlipidemia
Drug: SYH2070
Phase 2 Recruiting 2026-07 China
A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
NCT07465263 · ClinicalTrials.gov ↗ · Heterozygous Familial Hypercholesterolemia (HeFH)
Drug: SYH2053
Phase 3 Recruiting 2026-03 China
A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia
NCT07421297 · ClinicalTrials.gov ↗ · Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
Drug: SYH2053
Phase 3 Recruiting 2026-02 China
A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering Therapy
NCT07421284 · ClinicalTrials.gov ↗ · Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
Phase 3 Not yet open 2026-03 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in CSPC Zhongnuo Pharmaceutical (Shijiazhuang) trials

3 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in CSPC Zhongnuo Pharmaceutical (Shijiazhuang) trials

9 conditions
Non-familial Hypercholesterolemia and Mixed Hyperlipidemia2Healthy Chinese Volunteers1Healthy Subjects1Schizophrenia1Healthy Subjects (HS)1Diagnosed With HoFH1Bioequivalence1Mixed Hyperlipidemia1Heterozygous Familial Hypercholesterolemia (HeFH)1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China109

A trial with sites in more than one country appears in each of those registers.

05

Questions about CSPC Zhongnuo Pharmaceutical (Shijiazhuang) trials

How many clinical trials does CSPC Zhongnuo Pharmaceutical (Shijiazhuang) sponsor?

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) is the lead sponsor of 10 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are CSPC Zhongnuo Pharmaceutical (Shijiazhuang) trials recruiting?

Yes. 9 of its 10 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is CSPC Zhongnuo Pharmaceutical (Shijiazhuang) testing?

Its current trials name 3 drugs and biologicals as interventions. The most frequent are SYH2053 (2), SYH2070 (2) and Abraxane (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.